Vertex Pharmaceuticals Inc (VRTX) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

- Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY - - Agreement for CASGEVY in...

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

-- JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of...

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10...

Form 4 - Statement of changes in beneficial ownership of securities

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January...

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore

- Exclusive collaboration and licensing agreement for povetacicept in the region - - Zai Lab will leverage its local expertise and commercial...

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease...

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will...

Form 8-K - Current report